Anixa Biosciences, Inc.
(NASDAQ : ANIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.30%353.600.0%$6728.26m
BNTXBioNTech SE 5.04%328.350.0%$1093.01m
SNSSSunesis Pharmaceuticals, Inc. -2.32%10.520.7%$735.39m
NVAXNovavax, Inc. -2.54%179.3379.8%$649.04m
AMGNAmgen, Inc. -0.38%241.541.3%$499.24m
BIIBBiogen, Inc. -0.74%326.731.7%$431.26m
VRTXVertex Pharmaceuticals, Inc. 0.60%201.581.9%$414.73m
GILDGilead Sciences, Inc. -2.21%68.291.0%$401.30m
REGNRegeneron Pharmaceuticals, Inc. -1.46%574.612.7%$353.89m
ILMNIllumina, Inc. 0.84%495.753.5%$264.01m
NTLAIntellia Therapeutics, Inc. 3.53%141.852.3%$263.90m
CRSPCRISPR Therapeutics AG 1.70%121.020.6%$144.72m
EXASEXACT Sciences Corp. -3.64%107.8418.1%$123.59m
SGENSeagen Inc. 4.38%153.395.8%$120.23m
CYTKCytokinetics, Inc. 1.09%29.683.2%$115.29m

Company Profile

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.